This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.
product summary
company name :
R&D Systems
product type :
protein
product name :
Recombinant Mouse PD-L1/B7-H1 Fc Chimera Protein, CF
catalog :
1019-B7-100
quantity :
100 ug
price :
408 USD
citations: 23
Reference
Zhong W, Lu Y, Han X, Yang J, Qin Z, Zhang W, et al. Upregulation of exosome secretion from tumor-associated macrophages plays a key role in the suppression of anti-tumor immunity. Cell Rep. 2023;42:113224 pubmed publisher
Corria Osorio J, Carmona S, Stefanidis E, Andreatta M, Ortiz Miranda Y, Muller T, et al. Orthogonal cytokine engineering enables novel synthetic effector states escaping canonical exhaustion in tumor-rejecting CD8+ T cells. Nat Immunol. 2023;24:869-883 pubmed publisher
Meerschaert K, Edwards B, Epouhe A, Jefferson B, Friedman R, Babyok O, et al. Neuronally expressed PDL1, not PD1, suppresses acute nociception. Brain Behav Immun. 2022;106:233-246 pubmed publisher
Martins C, Silva M, Rasbach E, Singh P, Itoh Y, Williams J, et al. Distinct antibody clones detect PD-1 checkpoint expression and block PD-L1 interactions on live murine melanoma cells. Sci Rep. 2022;12:12491 pubmed publisher
Bryan C, Rocklin G, Bick M, Ford A, Majri Morrison S, Kroll A, et al. Computational design of a synthetic PD-1 agonist. Proc Natl Acad Sci U S A. 2021;118: pubmed publisher
Thanabalasuriar A, Chiang A, Morehouse C, Camara M, Hawkins S, Keller A, et al. PD-L1+ neutrophils contribute to injury-induced infection susceptibility. Sci Adv. 2021;7: pubmed publisher
Hanson A, Elpek K, Duong E, Shallberg L, Fan M, Johnson C, et al. ICOS agonism by JTX-2011 (vopratelimab) requires initial T cell priming and Fc cross-linking for optimal T cell activation and anti-tumor immunity in preclinical models. PLoS ONE. 2020;15:e0239595 pubmed publisher
Zalba S, Contreras Sandoval A, Martisova E, Debets R, Smerdou C, Garrido M. Quantification of Pharmacokinetic Profiles of PD-1/PD-L1 Antibodies by Validated ELISAs. Pharmaceutics. 2020;12: pubmed publisher
Garrett Thomson S, Massimi A, Fedorov E, Bonanno J, Scandiuzzi L, Hillerich B, et al. Mechanistic dissection of the PD-L1:B7-1 co-inhibitory immune complex. PLoS ONE. 2020;15:e0233578 pubmed publisher
Garo L, Ajay A, Fujiwara M, Beynon V, Kuhn C, Gabriely G, et al. Smad7 Controls Immunoregulatory PDL2/1-PD1 Signaling in Intestinal Inflammation and Autoimmunity. Cell Rep. 2019;28:3353-3366.e5 pubmed publisher
Nakajima M, Sakoda Y, Adachi K, Nagano H, Tamada K. Improved survival of chimeric antigen receptor-engineered T (CAR-T) and tumor-specific T cells caused by anti-programmed cell death protein 1 single-chain variable fragment-producing CAR-T cells. Cancer Sci. 2019;110:3079-3088 pubmed publisher
von Knethen A, Schäfer A, Kuchler L, Knape T, Christen U, Hintermann E, et al. Tolerizing CTL by Sustained Hepatic PD-L1 Expression Provides a New Therapy Approach in Mouse Sepsis. Theranostics. 2019;9:2003-2016 pubmed publisher
Xue X, Wu J, Li J, Xu J, Dai H, Tao C, et al. Indirubin attenuates mouse psoriasis-like skin lesion in a CD274-dependent manner: an achievement of RNA sequencing. Biosci Rep. 2018;38: pubmed publisher
Tsukamoto H, Fujieda K, Miyashita A, Fukushima S, Ikeda T, Kubo Y, et al. Combined Blockade of IL6 and PD-1/PD-L1 Signaling Abrogates Mutual Regulation of Their Immunosuppressive Effects in the Tumor Microenvironment. Cancer Res. 2018;78:5011-5022 pubmed publisher
Nakagawa S, Serada S, Kakubari R, Hiramatsu K, Sugase T, Matsuzaki S, et al. Intratumoral Delivery of an Adenoviral Vector Carrying the SOCS-1 Gene Enhances T-Cell-Mediated Antitumor Immunity By Suppressing PD-L1. Mol Cancer Ther. 2018;17:1941-1950 pubmed publisher
Rios Doria J, Harper J, Rothstein R, Wetzel L, Chesebrough J, MARRERO A, et al. Antibody-Drug Conjugates Bearing Pyrrolobenzodiazepine or Tubulysin Payloads Are Immunomodulatory and Synergize with Multiple Immunotherapies. Cancer Res. 2017;77:2686-2698 pubmed publisher
Kinosada H, Yasunaga J, Shimura K, Miyazato P, Onishi C, Iyoda T, et al. HTLV-1 bZIP Factor Enhances T-Cell Proliferation by Impeding the Suppressive Signaling of Co-inhibitory Receptors. PLoS Pathog. 2017;13:e1006120 pubmed publisher
Kleinpeter P, Fend L, Thioudellet C, Geist M, Sfrontato N, Koerper V, et al. Vectorization in an oncolytic vaccinia virus of an antibody, a Fab and a scFv against programmed cell death -1 (PD-1) allows their intratumoral delivery and an improved tumor-growth inhibition. Oncoimmunology. 2016;5:e1220467 pubmed
Shirakawa K, Yan X, Shinmura K, Endo J, Kataoka M, Katsumata Y, et al. Obesity accelerates T cell senescence in murine visceral adipose tissue. J Clin Invest. 2016;126:4626-4639 pubmed publisher
McAlees J, Lajoie S, Dienger K, Sproles A, Richgels P, Yang Y, et al. Differential control of CD4(+) T-cell subsets by the PD-1/PD-L1 axis in a mouse model of allergic asthma. Eur J Immunol. 2015;45:1019-29 pubmed publisher
Xiao Y, Yu S, Zhu B, Bedoret D, Bu X, Francisco L, et al. RGMb is a novel binding partner for PD-L2 and its engagement with PD-L2 promotes respiratory tolerance. J Exp Med. 2014;211:943-59 pubmed publisher
Drees J, Augustin L, Mertensotto M, Schottel J, Leonard A, Saltzman D. Soluble production of a biologically active single-chain antibody against murine PD-L1 in Escherichia coli. Protein Expr Purif. 2014;94:60-6 pubmed publisher
Butte M, Keir M, Phamduy T, Sharpe A, Freeman G. Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. Immunity. 2007;27:111-22 pubmed
product information
master code :
1019-B7
SKU :
1019-B7-100
product name :
Recombinant Mouse PD-L1/B7-H1 Fc Chimera Protein, CF
unit size :
100 ug
description :
The Recombinant Mouse PD-L1/B7-H1 Fc Chimera Protein, CF from R&D Systems is derived from NS0. The Recombinant Mouse PD-L1/B7-H1 Fc Chimera Protein, CF has been validated for the following applications: Bioactivity.
target :
PD-L1/B7-H1
category :
Proteins and Enzymes
buffer :
Lyophilized from a 0.2 ╡m filtered solution in PBS.
conjugate :
Unconjugated
purity :
>90%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie« Blue Staining.
species :
Mouse
observed molecular weight :
75-85 kDa, reducing conditions
theoretical molecular weight :
51.3 kDa (monomer)
gene symbol :
Cd274
details of functionality :
Measured by its ability to inhibit anti-CD3-induced proliferation of stimulated mouse T cells. The ED50 for this effect is 0.15-0.75 ╡g/mL.
endotoxin note :
<0.10 EU per 1 ╡g of the protein by the LAL method.
top caption :
Recombinant Mouse PD-L1/B7-H1 Fc Chimera Protein Bioactivity
accessionNumbers :
Q9EP73
applications :
Bioactivity
source long :
Mouse myeloma cell line, NS0-derived mouse PD-L1/B7-H1 protein Mouse PD-L1 (Phe19-Thr238) Accession # Q9EP73 IEGRMD Human IgG1 (Pro100-Lys330) N-terminus C-terminus
source short :
NS0
USD :
408 USD
alt names :
Avelumab, B7-H, B7H1, B7-H1, B7H1PDCD1L1, CD274, CD274 antigenMGC142294, CD274 molecule, PDCD1L1, PDCD1LG1, PDCD1LG1MGC142296, PDL1, PD-L1, PD-L1B7 homolog 1, PDL1PDCD1 ligand 1, programmed cell death 1 ligand 1, Programmed death ligand 1
storage :
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 ░C as supplied. 1 month, 2 to 8 ░C under sterile conditions after reconstitution. 3 months, -20 to -70 ░C under sterile conditions after reconstitution.
company information
R&D Systems
614 McKinley Place N.E.
Minneapolis, MN 55413
info@RnDSystems.com
https://www.rndsystems.com
800 343-7475
headquarters: USA
R&D Systems develops and manufactures high-quality proteins and serves as a world leader in immunoassays. R&D Systems also produces quality antibodies, antibody arrays, stem cell and cell culture products, and cell selection and detection products, serving the life science and diagnostics industry.